*Primary endpoint of non-inferiority vs aflibercept was defined as the mean change from baseline in BCVA (measured by the ETDRS letter score) to 1 year (average of weeks 40, 44, and 48 in nAMD and weeks 48, 52, and 56 in DME) and was tested for non-inferiority using a margin of 4 letters.1
†After 4 or 6 monthly loading doses.1 See additional information on the Dosing & Study Design page.
‡Verana Health data from Q1–Q4 2022.6
VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2023.
VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2023.
Beovu® (brolucizumab) [package insert]. East Hanover, NJ: Novartis; 2020.
Beovu® (brolucizumab) [package insert]. East Hanover, NJ: Novartis; 2020.
Eylea® (aflibercept) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2022.
Eylea® (aflibercept) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2022.
LUCENTIS® (ranibizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2018.
LUCENTIS® (ranibizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2018.
SUSVIMO™ (ranibizumab injection) [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO™ (ranibizumab injection) [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Data on file. South San Francisco, CA: Genentech, Inc.
Data on file. South San Francisco, CA: Genentech, Inc.
Regula JT, et al. EMBO Mol Med. 2016;8:1265-1288.
Regula JT, et al. EMBO Mol Med. 2016;8:1265-1288.
Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661.
Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661.
Fiedler U, et al. Trends Immunol. 2006;27(12):552-558.
Fiedler U, et al. Trends Immunol. 2006;27(12):552-558.
Hawighorst T, et al. American Journ of Pathol. 2002;160(4):1381-1392.
Hawighorst T, et al. American Journ of Pathol. 2002;160(4):1381-1392.
Avery RL, et al. Presented at American Association of Ophthalmology (AAO). Sept 30-Oct 03 2022.
Avery RL, et al. Presented at American Association of Ophthalmology (AAO). Sept 30-Oct 03 2022.
Heier J, et al. Lancet. 2022;399(10326):729-740.
Heier J, et al. Lancet. 2022;399(10326):729-740.
Guymer R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2022. Feb 11-12 2022.
Guymer R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2022. Feb 11-12 2022.
Wykoff C, et al. Lancet. 2022;399(10326):741-755.
Wykoff C, et al. Lancet. 2022;399(10326):741-755.
Baumal CR, et al. Presented at American Academy of Ophthalmology (AAO) 2022. Sep 30-Oct 03 2022.
Baumal CR, et al. Presented at American Academy of Ophthalmology (AAO) 2022. Sep 30-Oct 03 2022.
Heier JS, et al. Presented at American Academy of Ophthalmology Retina Subspecialty Day (AAO-SSD) 2021. Nov 12-13 2021.
Heier JS, et al. Presented at American Academy of Ophthalmology Retina Subspecialty Day (AAO-SSD) 2021. Nov 12-13 2021.
Baumal CR, et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022. May 1-4 2022.
Baumal CR, et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022. May 1-4 2022.
Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964-972.
Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964-972.
Sahni J, et al. Ophthalmology. 2019;126(8):1155-1170.
Sahni J, et al. Ophthalmology. 2019;126(8):1155-1170.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.